These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3607740)

  • 1. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
    Kim S; Kim DJ; Geyer MA; Howell SB
    Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivesicular liposomes containing cytarabine for slow-release Sc administration.
    Kim S; Howell SB
    Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy.
    Kim S; Howell SB
    Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.
    Kim S; Khatibi S; Howell SB; McCully C; Balis FM; Poplack DG
    Cancer Res; 1993 Apr; 53(7):1596-8. PubMed ID: 8453629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
    Angst MS; Drover DR
    Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release of liposome-encapsulated enrofloxacin after intramuscular administration in rabbits.
    Cabanes A; Reig F; Antón JM; Arboix M
    Am J Vet Res; 1995 Nov; 56(11):1498-501. PubMed ID: 8585663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye.
    Assil KK; Weinreb RN
    Arch Ophthalmol; 1987 Mar; 105(3):400-3. PubMed ID: 3827719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release of the antimetabolite 5-fluorouridine-5'-monophosphate by multivesicular liposomes.
    Assil KK; Lane J; Weinreb RN
    Ophthalmic Surg; 1988 Jun; 19(6):408-13. PubMed ID: 3419776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivesicular liposomes containing bleomycin for subcutaneous administration.
    Roy R; Kim S
    Cancer Chemother Pharmacol; 1991; 28(2):105-8. PubMed ID: 1711933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.
    Bleyer WA
    Clin Cancer Res; 1999 Nov; 5(11):3349-51. PubMed ID: 10589743
    [No Abstract]   [Full Text] [Related]  

  • 12. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H; Rustum Y; Mayhew E; Ledesma E
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes.
    Assil KK; Hartzer M; Weinreb RN; Nehorayan M; Ward T; Blumenkranz M
    Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2891-7. PubMed ID: 1917392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes.
    Kim S; Scheerer S; Geyer MA; Howell SB
    J Infect Dis; 1990 Sep; 162(3):750-2. PubMed ID: 2167343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro release and depot effect after intratumoral application of metrizamide-containing liposomes.
    Mentrup E; Wowra B; Zeller WJ; Sturm V; Stricker H
    Arzneimittelforschung; 1989 Apr; 39(4):421-3. PubMed ID: 2751728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
    Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
    Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.
    Juliano RL; McCullough HN
    J Pharmacol Exp Ther; 1980 Aug; 214(2):381-7. PubMed ID: 7391983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
    Rahman YE; Patel KR; Cerny EA; Maccoss M
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain.
    Smith LJ; Krugner-Higby L; Clark M; Wendland A; Heath TD
    Comp Med; 2003 Jun; 53(3):280-7. PubMed ID: 12868573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
    Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
    Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.